Archives by
Month/Year
November/December 2011 – The Shortcoming of Mandatory Generic Substitution
December 2011
IN THIS ISSUE...Look Out for 2012...Fighting the battle: Narcotic abuse Ontario...NOC Watch: Sublinox, Generic Latanoprost...FEATURE: The Story of Nexium®, Generic Esomeprazole and the Shortcoming of Mandatory Generic Substitution...Subsequent Entry Biologics: Expectations and Reality View post
Fighting The Battle: Narcotic Abuse Ontario
December 2011
On November 1, 2011, Ontario’s “Narcotics Safety and Awareness Act” came into force. This new legislation is intended to support the development of a narcotics monitoring database – the first component of Ontario’s new “Narcotics Strategy”, and one of five key elements View post
NOC Watch – Sublinox, Generic Latanoprost
December 2011
Sublinox® (Zolpidem) Already approved in several countries, including the Netherlands and the U.S., where it is sold under the familiar trade name Ambien®, Sublinox® is the first zolpidem product available in Canada. Sublinox® is a non-benzodiazepine sleep aid indicated for the short-term View post
The Story of Nexium®, Generic Esomeprazole and the Shortcoming of Mandatory Generic Substitution
December 2011
The case of the popular proton pump inhibitor (PPI) Nexium® (esomeprazole), a medication used to treat stomach hyperacidity, is very interesting. It belongs to a class of drugs with a number of very well-known generic alternatives which are widely considered to be View post
Subsequent Entry Biologics: Expectations and Reality
December 2011
Subsequent Entry Biologics (SEBs) are just that, biological drugs entering the market subsequent to a similar brand innovator product. There has been increasing interest in understanding what role SEBs might play in cost containment for plans moving forward. In order for a View post
Latest News
-
N.S. tightens rules on OxyContin -Globe and Mail (February 20, 2012) - Provinces become proactive after being accused of inaction in the face of rising addiction rates - Nova Scotia has become the latest... View post
-
Another Blockbuster Falls: Generic Plavix® Now Available - February 2012 - After over 8 years of patent challenges between the Canadian generic manufacturing company Apotex and the product’s innovator, sanofi-aventis, clopidogrel (generic for... View post
-
Protecting Your Plan from the Gravy Train - February 2012 - Although full-product direct-to-consumer advertising (DTCA) is illegal in Canada, most Canadians are exposed to this type of advertising through media spillage from... View post
-
Many Canadians can’t afford to take drugs as directed -Globe and Mail (January 17, 2012) - One in four Canadians who do not have drug insurance are unable to afford to take their prescription drugs as directed, a... View post
-
Look ahead with predictive modelling -Benefits Canada (January 2012) - The most recent 24 months of data is one of the most important pieces of information that plan sponsors and advisors have... Download PDF
-
Drug Plans Erode Over Last 20 Years -Benefits and Pensions monitor (December 2011) - All of us involved in the provision and management of drug plan benefits should be embarassed by the lack of progress over... Download PDF
-
Are we in 2002 or 2012? A word of caution about mail-order pharmacies -Benefits Canada (November 2011) - If a plan design does not support mail order (or any other preferred pharmacy arrangement) in a meaningful way, it will be... Download PDF
Connect
